secwatch.observer — SEC 8-K summary
======================================

Issuer:     Maze Therapeutics, Inc. (MAZE)
CIK:        0001842295
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0000950170-25-047207
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maze Therapeutics: Q4 net loss $29.6M, FY net income $52.2M on $167.5M license revenue; cash runway into H2 2027
--------------------------------------------------------------------------------

- Q4 net loss $29.6M vs $26.6M loss a year ago; FY net income $52.2M vs $100.4M loss in 2023.
- Cash and cash equivalents $196.8M as of Dec 31, 2024, up from $29.2M; combined with Feb 2025 IPO proceeds of $140M provides runway into H2 2027.
- License revenue of $167.5M in FY2024 primarily from $150M upfront from Shionogi for MZE001.
- Phase 2 HORIZON trial of MZE829 for AKD dosing patients; initial data expected Q1 2026.
- Phase 1 trial of MZE782 ongoing; initial data including proof-of-mechanism expected H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842295/000095017025047207/0000950170-25-047207-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842295/000095017025047207/maze-8k-q424_earnings.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-047207

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer